

Item 8.01. Other Events.

On October 13, 2016, TG Therapeutics, Inc. (the “Company”) issued a press release announcing amendments to the Company’s GENUINE Phase 3 clinical trial to accelerate study completion. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated October 13, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.
(Registrant)

Date: October 13, 2016

By: /s/ Sean A. Power
Sean A. Power
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit
Number Description

99.1. Press Release, dated October 13, 2016